SLN.Lライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications...

Stats
本日の出来高	913 528
平均出来高	104 775
時価総額	0.00
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.110
ATR14	£0 (0.00%)

Silence Therapeutics PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Silence Therapeutics PLC 財務諸表

Annual	2020
収益:	£5.48M
総利益:	£1.72M (31.34 %)
EPS:	£-0.398

FY	2020
収益:	£5.48M
総利益:	£1.72M (31.34 %)
EPS:	£-0.398

FY	2019
収益:	£244 000
総利益:	£0.00 (0.00 %)
EPS:	£-0.261

FY	2018
収益:	£0.00
総利益:	£0.00 (0.00 %)
EPS:	£-0.262

Financial Reports:

No articles found.

Silence Therapeutics PLC

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.